These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 29606064)

  • 61. Ketamine for the Treatment of Depression-Reply.
    Sanacora G
    JAMA Psychiatry; 2017 Sep; 74(9):971-972. PubMed ID: 28700772
    [No Abstract]   [Full Text] [Related]  

  • 62. Corrigendum to ``A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation''. [Journal of Affective Disorders 251 (2019) 205-212].
    Zhan Y; Zhang B; Zhou Y; Zheng W; Liu W; Wang C; Li H; Chen L; Yu L; Walter M; Li M; Li MD; Ning Y
    J Affect Disord; 2020 Sep; 274():1220. PubMed ID: 32663958
    [No Abstract]   [Full Text] [Related]  

  • 63. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial.
    Arabzadeh S; Hakkikazazi E; Shahmansouri N; Tafakhori A; Ghajar A; Jafarinia M; Akhondzadeh S
    J Affect Disord; 2018 Aug; 235():236-241. PubMed ID: 29660637
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Can a Framework Be Established for the Safe Use of Ketamine?
    Freedman R; Brown AS; Cannon TD; Druss BG; Earls FJ; Escobar J; Hurd YL; Lewis DA; López-Jaramillo C; Luby J; Mayberg HS; Moffitt TE; Oquendo M; Perlis RH; Pine DS; Rush AJ; Tamminga CA; Tohen M; Vieta E; Wisner KL; Xin Y
    Am J Psychiatry; 2018 Jul; 175(7):587-589. PubMed ID: 29656666
    [No Abstract]   [Full Text] [Related]  

  • 65. Treatment-resistant depression and suicidality.
    Bergfeld IO; Mantione M; Figee M; Schuurman PR; Lok A; Denys D
    J Affect Disord; 2018 Aug; 235():362-367. PubMed ID: 29665520
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
    Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
    Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
    Canuso CM; Singh JB; Fedgchin M; Alphs L; Lane R; Lim P; Pinter C; Hough D; Sanacora G; Manji H; Drevets WC
    Am J Psychiatry; 2018 Jul; 175(7):620-630. PubMed ID: 29656663
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
    Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
    Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ketamine reduces deleterious consequences of spreading depolarizations.
    Reinhart KM; Shuttleworth CW
    Exp Neurol; 2018 Jul; 305():121-128. PubMed ID: 29653188
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression.
    Ho MF; Correia C; Ingle JN; Kaddurah-Daouk R; Wang L; Kaufmann SH; Weinshilboum RM
    Biochem Pharmacol; 2018 Jun; 152():279-292. PubMed ID: 29621538
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?
    Abdallah CG; Sanacora G; Duman RS; Krystal JH
    Pharmacol Ther; 2018 Oct; 190():148-158. PubMed ID: 29803629
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study.
    Gamble JJ; Bi H; Bowen R; Weisgerber G; Sanjanwala R; Prasad R; Balbuena L
    Can J Anaesth; 2018 Jun; 65(6):636-646. PubMed ID: 29700801
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
    McIntyre RS; Rosenblat JD; Nemeroff CB; Sanacora G; Murrough JW; Berk M; Brietzke E; Dodd S; Gorwood P; Ho R; Iosifescu DV; Lopez Jaramillo C; Kasper S; Kratiuk K; Lee JG; Lee Y; Lui LMW; Mansur RB; Papakostas GI; Subramaniapillai M; Thase M; Vieta E; Young AH; Zarate CA; Stahl S
    Am J Psychiatry; 2021 May; 178(5):383-399. PubMed ID: 33726522
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Glutamatergic Modulators for Major Depression from Theory to Clinical Use.
    McIntyre RS; Jain R
    CNS Drugs; 2024 Nov; 38(11):869-890. PubMed ID: 39150594
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Electroconvulsive therapy (ECT) with ketamine induction for catatonia in an HIV positive patient.
    Nel Y; Bracken CA
    S Afr J Psychiatr; 2023; 29():1944. PubMed ID: 36756540
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine.
    Cardona-Acosta AM; Bolaños-Guzmán CA
    Neuropharmacology; 2023 Mar; 225():109374. PubMed ID: 36516891
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety of Repeated Administration of Parenteral Ketamine for Depression.
    Feifel D; Dadiomov D; C Lee K
    Pharmaceuticals (Basel); 2020 Jul; 13(7):. PubMed ID: 32668686
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
    Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
    Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Neuroscience-Informed Treatments.
    Focus (Am Psychiatr Publ); 2019 Jan; 17(1):50-51. PubMed ID: 31975961
    [No Abstract]   [Full Text] [Related]  

  • 80. Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors.
    De Berardis D; Fornaro M; Valchera A; Cavuto M; Perna G; Di Nicola M; Serafini G; Carano A; Pompili M; Vellante F; Orsolini L; Fiengo A; Ventriglio A; Yong-Ku K; Martinotti G; Di Giannantonio M; Tomasetti C
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30249029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.